78 related articles for article (PubMed ID: 10850420)
1. The von Hippel-Lindau tumor suppressor targets to mitochondria.
Shiao YH; Resau JH; Nagashima K; Anderson LM; Ramakrishna G
Cancer Res; 2000 Jun; 60(11):2816-9. PubMed ID: 10850420
[TBL] [Abstract][Full Text] [Related]
2. Endoplasmic reticulum/cytosolic localization of von Hippel-Lindau gene products is mediated by a 64-amino acid region.
Schoenfeld AR; Davidowitz EJ; Burk RD
Int J Cancer; 2001 Feb; 91(4):457-67. PubMed ID: 11251966
[TBL] [Abstract][Full Text] [Related]
3. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
[TBL] [Abstract][Full Text] [Related]
4. Role of nuclear and cytoplasmic localization in the tumour-suppressor activity of the von Hippel-Lindau protein.
Lewis MD; Roberts BJ
Oncogene; 2003 Jun; 22(26):3992-7. PubMed ID: 12821933
[TBL] [Abstract][Full Text] [Related]
5. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
[TBL] [Abstract][Full Text] [Related]
6. Renal cell carcinoma development in the rat independent of alterations at the VHL gene locus.
Walker C; Ahn YT; Everitt J; Yuan X
Mol Carcinog; 1996 Feb; 15(2):154-61. PubMed ID: 8599582
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
8. Expression pattern of the von Hippel-Lindau protein in human tissues.
Los M; Jansen GH; Kaelin WG; Lips CJ; Blijham GH; Voest EE
Lab Invest; 1996 Aug; 75(2):231-8. PubMed ID: 8765323
[TBL] [Abstract][Full Text] [Related]
9. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density.
Lee S; Chen DY; Humphrey JS; Gnarra JR; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1770-5. PubMed ID: 8700833
[TBL] [Abstract][Full Text] [Related]
10. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2.
Groulx I; Bonicalzi ME; Lee S
J Biol Chem; 2000 Mar; 275(12):8991-9000. PubMed ID: 10722748
[TBL] [Abstract][Full Text] [Related]
11. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues.
Corless CL; Kibel AS; Iliopoulos O; Kaelin WG
Hum Pathol; 1997 Apr; 28(4):459-64. PubMed ID: 9104946
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
13. Role of the von Hippel-Lindau tumor suppressor protein during neuronal differentiation.
Kanno H; Saljooque F; Yamamoto I; Hattori S; Yao M; Shuin T; U HS
Cancer Res; 2000 Jun; 60(11):2820-4. PubMed ID: 10850421
[TBL] [Abstract][Full Text] [Related]
14. The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1.
Zhou MI; Wang H; Ross JJ; Kuzmin I; Xu C; Cohen HT
J Biol Chem; 2002 Oct; 277(42):39887-98. PubMed ID: 12169691
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma.
Ananth S; Knebelmann B; Grüning W; Dhanabal M; Walz G; Stillman IE; Sukhatme VP
Cancer Res; 1999 May; 59(9):2210-6. PubMed ID: 10232610
[TBL] [Abstract][Full Text] [Related]
16. Von Hippel-Lindau disease and sporadic renal cell carcinoma.
Zbar B
Cancer Surv; 1995; 25():219-32. PubMed ID: 8718521
[TBL] [Abstract][Full Text] [Related]
17. von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
Lieubeau-Teillet B; Rak J; Jothy S; Iliopoulos O; Kaelin W; Kerbel RS
Cancer Res; 1998 Nov; 58(21):4957-62. PubMed ID: 9810005
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations.
Duan DR; Humphrey JS; Chen DY; Weng Y; Sukegawa J; Lee S; Gnarra JR; Linehan WM; Klausner RD
Proc Natl Acad Sci U S A; 1995 Jul; 92(14):6459-63. PubMed ID: 7604013
[TBL] [Abstract][Full Text] [Related]
19. Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann B; Ananth S; Cohen HT; Sukhatme VP
Cancer Res; 1998 Jan; 58(2):226-31. PubMed ID: 9443397
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
